Global law firm White & Case LLP has advised Neopharmed Gentili, an Italian pharmaceutical company active in the marketing of high value therapeutic solutions, on the acquisition of the European business of ORLADEYO® (berotralstat) from BioCryst Pharmaceuticals.
This strategic acquisition strengthens the company’s presence in the rare diseases sector across Europe and is expected to close in October 2025. It supports Neopharmed Gentili, controlled by the Del Bono family along with Ardian and Renaissance Partners, in expanding its portfolio into a high growth, high value therapeutic area. The deal includes an upfront payment of US$250 million with potential additional consideration of up to US$14 million linked to commercial milestones.
The White & Case transaction team, which also provided mergers and acquisitions and corporate advice, was led by partner Michael Immordino (London & Milan) and included associates Elena Ruggiu and Valerio Bianchi (both Milan) and lawyers Artem Arzumanov, Nicola Acconcia and Lucia Onofri (all Milan). Intellectual property expertise was provided by partner Anita Varma (Boston & London), counsel Ajita Shukla (Washington, DC) and associates Nashel Jung (New York), Temi Ajibode (New York) and technical advisor Joanne Holland (Boston). Tax expertise was provided by partner Scott Fryman (New York). FDA and EMA advice was provided by partner Bethany Hills (New York) and counsel Katrin Helle (Berlin). Antitrust expertise was provided by partner Strati Sakellariou-Witt (Brussels) and associates Tommaso Poli (Brussels & Milan) and Roberto Giorgetti (Brussels). FDI expertise was provided by partner Orion Berg (Paris), counsel Tommaso Tosi (Milan) and associate Francesco Balestra (Milan). White & Case also advised on the financing of the transaction with a team led by partners Evgeny Scirtò Ostrovskiy (Milan & London) and Stefano Bellani (Milan) and including associate Nicola Tosin (Milan) and lawyer Noemi Stimamiglio (Milan).
Press contact
For more information please speak to your local media contact.
Read the orginal article: https://www.whitecase.com/news/press-release/white-case-advises-neopharmed-gentili-acquisition-orladeyors-european-business